Indications for: WYNZORA
≥18yrs: apply to affected areas once daily for up to 8 weeks; max 100g per week. Discontinue when control is achieved. Do not occlude.
<18yrs: not established.
Not for oral, ophthalmic, or intravaginal use. Avoid eyes, face, groin, axillae, or if skin atrophy is present at the treatment site. Discontinue if hypercalcemia or hypercalciuria develop; may resume once calcium metabolism has normalized. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, or hyperglycemia occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Allergic contact dermatitis. Pregnancy. Nursing mothers.
Vit. D3 derivative + topical steroid.
Systemic absorption potentiated by other corticosteroids.
Upper respiratory infection, headache, application site irritation.
Generic Drug Availability: